Fig 1.
Clinical characteristics of NPM1 positive AML patients.
aRemission was defined as morphologic leukemia-free state (MLFS) after induction. bDNA not available at the time point of relapse.
Fig 2.
Clinical characteristics of IDH1 and IDH2 positive AML patients.
aRemission was defined as morphologic leukemia-free state (MLFS) after induction. bDNA not available at relapse. cDNA not available at diagnosis for IDH1/2 testing.
Fig 3.
Probability of overall survival and relapse free survival according to NPM1 MRD after induction.
On both panels (A: overall survival; B: relapse free survival), the outcome of NPM1 MRD-negative (MRDneg VAF<0.01–0.05% depending on NPM1 mutation type) and MRD-positive (MRDpos VAF>0.01–0.05%) subgroups are shown with the associated p1 value. The NPM1 MRD-positive subgroup was further divided in MRD low-positive (MRDlow VAF = 0.01–0.2%) and MRD high-positive (MRDhigh VAF> 0.2%) subgroups, and compared with p2 values.
Table 1.
Multivariate analysis of NPM1 MRD status after induction.
Fig 4.
Overall survival and relapse free survival according to NPM1 MRD stratified by FLT3-ITD allelic ratio.
Based on the ELN 2017 genetic risk stratification, NPM1 positive patients were categorized in to favorable (FLT3-ITDneg/low) and intermediate (FLT3-ITDhigh) subgroups. On both panels (A: overall survival; B: relapse free survival), further subgroups were established according to NPM1 MRD after induction. NPM1 MRD negativity was defined as VAF<0.01–0.05% depending on mutation type.
Fig 5.
Overall survival according to NPM1 MRD measured before HSCT.
NPM1 MRD negativity before HSCT was defined as VAF<0.01–0.05% depending on mutation type.
Fig 6.
Overall survival and relapse free survival according to IDH1/2 MRD after induction.
On both panels (A: overall survival; B: relapse free survival) IDH1/2 MRD negativity defined as VAF<0.2% and MRD positivity as VAF>0.2%.
Table 2.
Multivariate analysis of IDH1/2 MRD status after induction.
Fig 7.
Probability of overall survival for IDH1/2 MRD before HSCT.
On panel A, IDH1/2 MRD negativity before HSCT was defined as VAF<0.2%, on panel B as 2.5%.